DURATION-2, a randomised, double-blind, double-dummy,multi-center clinical trial conducted in the USA, India andMexico was designed as a two-st age trial. In the ﬁrst phase, the efﬁcacy and safety of 26 weeks of treatment with exenatide once- weekly were compared with maximum approved doses of sitagliptin or pioglitazone in patients with Type 2 diabetes mellitus treated with metformin [3]. In this second, open-label phase, randomised oral medicati ons were discontinued and all patients received exenatide once-weekly. Randomization and interventions Eligible patients were male and non-pregnant female patients, at least18 yearsofage,withType 2diabetesmellitus,butotherwisehealthy and treated with a stable regimen of metformin for aminimum of 2 months prior to screening. Additional inclusioncriteriaincludedHbA 1c7.1–11.0%(54–97 mmol ⁄mol)andBMI 25–45 kg ⁄m2[3]. Patients ( n= 514) were originally randomised to one of three treatment groups by UBC Clinical Technologies